Insider transactions

EDGAR

C4 THERAPEUTICS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-17.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
2 transactions, 55,173 shares
Sum of shares × price per share: 144,686.5895

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 53

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-12 Filed 2026-11-13Adams Kendra Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)45,1732.7115
122,486.5895

Derived: shares × price per share. Exact value 122486.5895.

337,150Direct (D) Yes
F1, F2
  • F1 These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2026.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.645 to $2.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Open filing 0001470831-26-001003 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02Anderson Kenneth Carl Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,6623.14
11,498.68

Derived: shares × price per share. Exact value 11498.68.

75,612Direct (D) No
F1, F2
  • F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
  • F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026.
Open filing 0001470831-26-000925 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02GROGAN DONNA ROY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)4,6183.14
14,500.52

Derived: shares × price per share. Exact value 14500.52.

79,471Direct (D) No
F1, F2
  • F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
  • F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026.
Open filing 0001470831-26-000924 Read from the filing’s XML Dispute this row
2026-09-18 Filed 2026-09-21Adams Kendra Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6,2500—385,098Direct (D) No
F1
  • F1 Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units (RSUs). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on September 19, 2023.
Open filing 0001470831-26-000895 Read from the filing’s XML Dispute this row
2026-09-18 Filed 2026-09-21Adams Kendra Officer: Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,7753.39
9,407.25

Derived: shares × price per share. Exact value 9407.25.

382,323Direct (D) No
F2
  • F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000895 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-13REYNO LEONARD Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)15,3250—379,803Direct (D) No
F1
  • F1 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of restricted stock units (RSUs). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on July 12, 2023.
Open filing 0001470831-26-000705 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-13REYNO LEONARD Officer: Chief Medical Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)7,3974.06
30,031.82

Derived: shares × price per share. Exact value 30031.82.

372,406Direct (D) No
F2
  • F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000705 Read from the filing’s XML Dispute this row
2026-07-01 Filed 2026-07-02GROGAN DONNA ROY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,3414.34
14,499.94

Derived: shares × price per share. Exact value 14499.94.

74,853Direct (D) No
F1, F2
  • F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
  • F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026.
Open filing 0001470831-26-000689 Read from the filing’s XML Dispute this row
2026-07-01 Filed 2026-07-02Anderson Kenneth Carl Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,6504.34
11,501

Derived: shares × price per share. Exact value 11501.00.

71,950Direct (D) No
F1, F2
  • F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
  • F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026.
Open filing 0001470831-26-000688 Read from the filing’s XML Dispute this row
2026-06-24 Filed 2026-06-26Koppikar Utpal Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (62,000) — exercise price 4.25
Acquired (A)62,0000—62,000Direct (D) No
F1
  • F1 This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Open filing 0001470831-26-000667 Read from the filing’s XML Dispute this row
2026-06-24 Filed 2026-06-26GROGAN DONNA ROY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (62,000) — exercise price 4.25
Acquired (A)62,0000—62,000Direct (D) No
F1
  • F1 This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Open filing 0001470831-26-000657 Read from the filing’s XML Dispute this row
2026-06-24 Filed 2026-06-26Fawell Stephen Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (62,000) — exercise price 4.25
Acquired (A)62,0000—62,000Direct (D) No
F1
  • F1 This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Open filing 0001470831-26-000659 Read from the filing’s XML Dispute this row
2026-06-24 Filed 2026-06-26Anderson Kenneth Carl Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (62,000) — exercise price 4.25
Acquired (A)62,0000—62,000Direct (D) No
F1
  • F1 This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Open filing 0001470831-26-000665 Read from the filing’s XML Dispute this row
2026-06-24 Filed 2026-06-26Bessen Laura Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (62,000) — exercise price 4.25
Acquired (A)62,0000—62,000Direct (D) No
F1
  • F1 This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Open filing 0001470831-26-000661 Read from the filing’s XML Dispute this row
2026-06-24 Filed 2026-06-26Hughes Owen Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (62,000) — exercise price 4.25
Acquired (A)62,0000—62,000Direct (D) No
F1
  • F1 This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Open filing 0001470831-26-000673 Read from the filing’s XML Dispute this row
2026-06-24 Filed 2026-06-26Hoerter Steven L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (62,000) — exercise price 4.25
Acquired (A)62,0000—62,000Direct (D) No
F1
  • F1 This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Open filing 0001470831-26-000670 Read from the filing’s XML Dispute this row
2026-06-24 Filed 2026-06-26Cooper Ronald Harold Wilfred Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (62,000) — exercise price 4.25
Acquired (A)62,0000—62,000Direct (D) No
F1
  • F1 This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Open filing 0001470831-26-000663 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-04Anderson Kenneth Carl Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,0702.11
2,257.7

Derived: shares × price per share. Exact value 2257.70.

69,300Direct (D) No
F1
  • F1 The reported transaction represents the exercise of a stock option for cash. No shares were sold in connection with the exercise.
Open filing 0001470831-26-000504 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-04Anderson Kenneth Carl Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (1,070) — exercise price 2.11
Disposed (D)1,0700—0Direct (D) No
F1, F7
  • F1 The reported transaction represents the exercise of a stock option for cash. No shares were sold in connection with the exercise.
  • F7 The shares underlying this option are fully vested and exercisable.
Open filing 0001470831-26-000504 Read from the filing’s XML Dispute this row
2026-04-01 Filed 2026-04-03Anderson Kenneth Carl Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)4,2592.70
11,499.3

Derived: shares × price per share. Exact value 11499.30.

68,230Direct (D) No
F1, F2
  • F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
  • F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2026.
Open filing 0001470831-26-000346 Read from the filing’s XML Dispute this row
2026-04-01 Filed 2026-04-03GROGAN DONNA ROY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)5,3702.70
14,499

Derived: shares × price per share. Exact value 14499.00.

71,512Direct (D) No
F1, F2
  • F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
  • F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2026.
Open filing 0001470831-26-000345 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Hirsch Andrew Director · Officer: President CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)20,4000—1,083,991Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025.
Open filing 0001470831-26-000177 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Hirsch Andrew Director · Officer: President CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)9,0571.89
17,117.73

Derived: shares × price per share. Exact value 17117.73.

1,074,934Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000177 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Adams Kendra Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)30,9500—400,479Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
Open filing 0001470831-26-000175 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Adams Kendra Officer: Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)15,3811.89
29,070.09

Derived: shares × price per share. Exact value 29070.09.

385,098Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000175 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Boyle Scott N Officer: Chief Business Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)20,9500—306,070Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
Open filing 0001470831-26-000180 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Boyle Scott N Officer: Chief Business Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)7,2691.89
13,738.41

Derived: shares × price per share. Exact value 13738.41.

298,801Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
Open filing 0001470831-26-000180 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Mahaney Paige Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)7,0500—339,356Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of RSUs. The grant of RSUs was initially reported in Table I of the Forms 4 filed by the Reporting Person on February 18, 2025.
Open filing 0001470831-26-000179 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Mahaney Paige Officer: Chief Scientific Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,4461.89
4,622.94

Derived: shares × price per share. Exact value 4622.94.

336,910Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000179 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Mossler Mark Officer: Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)9,4200—75,184Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on April 10, 2024 and February 18, 2025.
Open filing 0001470831-26-000174 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Mossler Mark Officer: Chief Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)3,2681.89
6,176.52

Derived: shares × price per share. Exact value 6176.52.

71,916Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000174 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Schick Kelly Officer: Chief People Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)20,9500—307,150Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
Open filing 0001470831-26-000178 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Schick Kelly Officer: Chief People Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)7,2691.89
13,738.41

Derived: shares × price per share. Exact value 13738.41.

299,881Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000178 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18REYNO LEONARD Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)30,9500—396,382Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 14, 2024 and February 18, 2025.
Open filing 0001470831-26-000176 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18REYNO LEONARD Officer: Chief Medical Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)16,5791.89
31,334.31

Derived: shares × price per share. Exact value 31334.31.

379,803Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000176 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Hirsch Andrew Director · Officer: President CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)81,7250—1,123,145Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025.
Open filing 0001470831-26-000177 Read from the filing’s XML Dispute this row
2026-02-14 Filed 2026-02-18Hirsch Andrew Director · Officer: President CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)39,1541.89
74,001.06

Derived: shares × price per share. Exact value 74001.06.

1,083,991Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000177 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Adams Kendra Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)240,0000—402,342Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
Open filing 0001470831-26-000175 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Adams Kendra Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,7500—402,342Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
Open filing 0001470831-26-000175 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Adams Kendra Officer: Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,8631.89
3,521.07

Derived: shares × price per share. Exact value 3521.07.

400,479Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000175 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Boyle Scott N Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)200,0000—307,805Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
Open filing 0001470831-26-000180 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Boyle Scott N Officer: Chief Business Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,0000—307,805Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
Open filing 0001470831-26-000180 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Boyle Scott N Officer: Chief Business Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,7351.89
3,279.15

Derived: shares × price per share. Exact value 3279.15.

306,070Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000180 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Mahaney Paige Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)240,0000—339,356Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
Open filing 0001470831-26-000179 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Mossler Mark Officer: Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)56,9800—75,184Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 28,490 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 28,490 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
Open filing 0001470831-26-000174 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Schick Kelly Officer: Chief People Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)200,0000—308,885Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
Open filing 0001470831-26-000178 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Schick Kelly Officer: Chief People Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,0000—308,885Direct (D) No
F2
  • F2 Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
Open filing 0001470831-26-000178 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Schick Kelly Officer: Chief People Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,7351.89
3,279.15

Derived: shares × price per share. Exact value 3279.15.

307,150Direct (D) No
F3
  • F3 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Open filing 0001470831-26-000178 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18REYNO LEONARD Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)240,0000—396,382Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
Open filing 0001470831-26-000176 Read from the filing’s XML Dispute this row
2026-02-13 Filed 2026-02-18Hirsch Andrew Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)700,0000—1,123,145Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
Open filing 0001470831-26-000177 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,793 filings read, the latest filed 2026-11-16. Prior quarter ending 2026-06-30: 9,164 filings read.

Showing 1–50 of 161

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Squadron Capital Management LLC 9,318,683 SH31,031,214 dollarsHigher by 2,118,683 Prior quarter: 7,200,000Open filing 0002050709-26-000036 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager8,872,634 SH29,545,871 dollarsHigher by 5,296 Prior quarter: 8,867,338Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
RA CAPITAL MANAGEMENT, L.P. 8,194,779 SH27,288,614 dollarsHigher by 194,779 Prior quarter: 8,000,000Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager8,179,926 SH27,239,155 dollarsHigher by 283,208 Prior quarter: 7,896,718Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Lynx1 Capital Management LP Partly reported under another manager7,530,915 SH25,077,947 dollarsHigher by 204,224 Prior quarter: 7,326,691Open filing 0001910456-26-000007 Filed 2026-11-16 Dispute this row
Bain Capital Life Sciences Investors, LLC 7,171,910 SH23,882,460 dollarsUnchanged Prior quarter: 7,171,910Open filing 0001193125-26-462089 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager5,006,879 SH16,672,907 dollarsHigher by 819,299 Prior quarter: 4,187,580Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager4,696,984 SH14,701,559 dollarsLower by 50,440 Prior quarter: 4,747,424Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager4,683,379 SH15,595,652 dollarsHigher by 1,152,388 Prior quarter: 3,530,991Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 4,581,502 SH15,256,402 dollarsHigher by 163,771 Prior quarter: 4,417,731Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
WASATCH ADVISORS LP Partly reported under another manager4,160,048 SH13,852,960 dollarsHigher by 637,404 Prior quarter: 3,522,644Open filing 0000814133-26-000137 Filed 2026-10-13 Dispute this row
Boxer Capital Management, LLC 4,150,000 SH13,819,500 dollarsNot in the prior quarter’s filings read Open filing 0001213900-26-120704 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 3,746,738 SH12,476,638 dollarsHigher by 277,031 Prior quarter: 3,469,707Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
SILVERARC CAPITAL MANAGEMENT, LLC 3,454,647 SH11,503,975 dollarsHigher by 422,587 Prior quarter: 3,032,060Open filing 0001420506-26-002577 Filed 2026-11-12 Dispute this row
Soleus Capital Management, L.P. 3,357,981 SH11,182,077 dollarsLower by 20,000 Prior quarter: 3,377,981Open filing 0001802630-26-000008 Filed 2026-11-16 Dispute this row
STEMPOINT CAPITAL LP 3,293,376 SH10,966,942 dollarsHigher by 2,769,728 Prior quarter: 523,648Open filing 0001420506-26-002774 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager2,890,772 SH9,626,270 dollarsHigher by 234,413 Prior quarter: 2,656,359Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Candriam S.C.A. 2,760,346 SH9,225,536 dollarsHigher by 963,409 Prior quarter: 1,796,937Open filing 0001537014-26-000009 Filed 2026-11-03 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager2,699,545 SH8,991,069 dollarsHigher by 177,382 Prior quarter: 2,522,163Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Qube Research Technologies Ltd 2,397,086 SH7,982,296 dollarsHigher by 2,026,532 Prior quarter: 370,554Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
ADAR1 Capital Management, LLC 2,232,857 SH7,435,414 dollarsHigher by 1,940,900 Prior quarter: 291,957Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager2,218,580 SH7,387,871 dollarsHigher by 102,959 Prior quarter: 2,115,621Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager2,162,093 SH7,199,770 dollarsHigher by 421,104 Prior quarter: 1,740,989Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
Ikarian Capital, LLC 1,933,000 SH6,436,890 dollarsLower by 500,000 Prior quarter: 2,433,000Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager1,787,391 SH5,950 dollarsLower by 18,808 Prior quarter: 1,806,199Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager1,384,966 SH4,609,336 dollarsHigher by 196,459 Prior quarter: 1,188,507Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
CONGRESS ASSET MANAGEMENT CO 1,256,692 SH4,184,784 dollarsHigher by 253,255 Prior quarter: 1,003,437Open filing 0000897378-26-000015 Filed 2026-10-06 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,234,707 SH4,111,574 dollarsHigher by 453,647 Prior quarter: 781,060Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager1,209,376 SH4,027,222 dollarsHigher by 19,548 Prior quarter: 1,189,828Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
FMR LLC Partly reported under another manager1,175,723 SH3,915,157 dollarsHigher by 281,669 Prior quarter: 894,054Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager1,157,394 SH3,854,121 dollarsLower by 3,153 Prior quarter: 1,160,547Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 1,094,194 SH3,643,666 dollarsHigher by 414,100 Prior quarter: 680,094Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
Atom Investors LP 911,528 SH3,035,388 dollarsHigher by 547,177 Prior quarter: 364,351Open filing 0001214659-26-014237 Filed 2026-11-16 Dispute this row
HighVista Strategies LLC 873,277 SH2,908,012 dollarsLower by 474,859 Prior quarter: 1,348,136Open filing 0001172661-26-004983 Filed 2026-11-13 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager855,805 SH2,849,832 dollarsHigher by 628,802 Prior quarter: 227,003Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
AQR CAPITAL MANAGEMENT LLC 767,992 SH2,557,413 dollarsNot in the prior quarter’s filings read Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager737,000 SH2,454,210 dollarsHigher by 477,700 Prior quarter: 259,300Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 721,744 SH2,403,408 dollarsHigher by 112,598 Prior quarter: 609,146Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
PANAGORA ASSET MANAGEMENT INC 690,687 SH2,299,988 dollarsHigher by 425,740 Prior quarter: 264,947Open filing 0000883677-26-000011 Filed 2026-11-12 Dispute this row
Nuveen, LLC Partly reported under another manager591,832 SH1,970,800 dollarsHigher by 107,822 Prior quarter: 484,010Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
BOOTHBAY FUND MANAGEMENT, LLC 585,009 SH1,948,080 dollarsLower by 151,322 Prior quarter: 736,331Open filing 0001549230-26-000012 Filed 2026-11-16 Dispute this row
PLATINUM INVESTMENT MANAGEMENT LTD 577,534 SH1,923,188 dollarsHigher by 192,768 Prior quarter: 384,766Open filing 0001256071-26-000016 Filed 2026-11-16 Dispute this row
Connor, Clark Lunn Investment Management Ltd. 546,352 SH1,819,352 dollarsHigher by 245,618 Prior quarter: 300,734Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row
Rockefeller Capital Management L.P. Partly reported under another manager517,591 SH1,723,578 dollarsHigher by 21,774 Prior quarter: 495,817Open filing 0001739439-26-000009 Filed 2026-11-13 Dispute this row
Squarepoint Ops LLC Partly reported under another manager516,551 SH1,720,115 dollarsHigher by 345,717 Prior quarter: 170,834Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
Ikarian Capital, LLC Option: Call 500,000 SH1,665,000 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager494,965 SH1,648,233 dollarsLower by 1,237,245 Prior quarter: 1,732,210Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
SCHRODER INVESTMENT MANAGEMENT GROUP Partly reported under another manager451,930 SH1,414,541 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-044129 Filed 2026-11-16 Dispute this row
Squadron Capital Management LLC Option: Call 400,000 SH1,332,000 dollarsUnchanged Prior quarter: 400,000Open filing 0002050709-26-000036 Filed 2026-11-16 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager396,270 SH1,319,579 dollarsLower by 56,431 Prior quarter: 452,701Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Patient Square Capital LP 1,608,815 SH
  • Sixth Street Partners Management Company, L.P. 781,060 SH
  • ExodusPoint Capital Management, LP 580,195 SH
  • ADAGE CAPITAL PARTNERS GP, L.L.C. 325,000 SH
  • Headlands Technologies LLC 153,972 SH
  • Virtu Financial LLC 98,094 SH
  • Aster Capital Management (DIFC) Ltd 77,734 SH
  • Jain Global LLC 57,562 SH
  • Thrivent Financial for Lutherans 52,763 SH
  • Quadrature Capital Ltd 36,726 SH
  • Dynamic Technology Lab Private Ltd 32,828 SH
  • JACOBS LEVY EQUITY MANAGEMENT, INC 25,111 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 24,100 SH
  • StoneX Group Inc. 22,420 SH
  • Scientech Research LLC 21,260 SH
  • Quantbot Technologies LP 20,827 SH
  • INTECH INVESTMENT MANAGEMENT LLC 19,602 SH
  • State of Wyoming 16,093 SH
  • ALGERT GLOBAL LLC 16,040 SH
  • EWA, LLC 14,129 SH
  • HSBC HOLDINGS PLC 13,629 SH
  • Northern Lights Advisors, Inc. 12,930 SH
  • RAYMOND JAMES FINANCIAL INC 11,860 SH
  • WINTON GROUP Ltd 11,100 SH
  • AXQ CAPITAL, LP 10,745 SH
  • PFG Investments, LLC 10,000 SH
  • SUMMIT SECURITIES GROUP LLC 829 SH
  • Integrated Wealth Concepts LLC 662 SH
  • Optiver Holding B.V. 358 SH
  • Walleye Capital LLC 300 SH
  • HUNTINGTON NATIONAL BANK 107 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Squadron Master Fund LP Common Stock, $0.0001 par value per share7.99,718,683.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0002050709-26-000030 Dispute this row
Squadron Capital Management LLC Common Stock, $0.0001 par value per share7.99,718,683.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0002050709-26-000030 Dispute this row
Matthew Sesterhenn Common Stock, $0.0001 par value per share7.99,718,683.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0002050709-26-000030 Dispute this row
William Blank Common Stock, $0.0001 par value per share7.99,718,683.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0002050709-26-000030 Dispute this row
RA Capital Management, L.P. Common Stock, $0.0001 par value per share9.913,654,272.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000277 Dispute this row
Peter Kolchinsky Common Stock, $0.0001 par value per share9.913,654,272.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000277 Dispute this row
Rajeev Shah Common Stock, $0.0001 par value per share9.913,654,272.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000277 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.0001 par value per share9.913,654,272.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000277 Dispute this row
RA Capital Management, L.P. Common Stock, $0.0001 par value per share9.911,383,696.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000920 Dispute this row
Peter Kolchinsky Common Stock, $0.0001 par value per share9.911,383,696.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000920 Dispute this row
Rajeev Shah Common Stock, $0.0001 par value per share9.911,383,696.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000920 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.0001 par value per share9.911,383,696.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000920 Dispute this row
Lynx1 Capital Management LP Common Stock, $0.0001 par value per share9.9915,423,691.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0000902664-26-003524 Dispute this row
Weston Nichols Common Stock, $0.0001 par value per share9.9915,423,691.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0000902664-26-003524 Dispute this row
Squadron Master Fund LP Common Stock, $0.0001 par value per share6.97,600,000.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0002050709-26-000022 Dispute this row
Squadron Capital Management LLC Common Stock, $0.0001 par value per share6.97,600,000.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0002050709-26-000022 Dispute this row
Matthew Sesterhenn Common Stock, $0.0001 par value per share6.97,600,000.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0002050709-26-000022 Dispute this row
William Blank Common Stock, $0.0001 par value per share6.97,600,000.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0002050709-26-000022 Dispute this row
Morgan Stanley Common Stock8.08,862,00206/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 3Open filing 0000895421-26-000231 Dispute this row
Morgan Stanley Capital Services LLC Common Stock7.98,718,00006/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 3Open filing 0000895421-26-000231 Dispute this row
Morgan Stanley Co. LLC Common Stock0.1134,04706/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 3Open filing 0000895421-26-000231 Dispute this row
BlackRock, Inc. Common Stock6.97,678,90606/30/2026 Filed 2026-07-27SCHEDULE 13GOpen filing 0002012383-26-002217 Dispute this row
Squadron Master Fund LP Common Stock, $0.0001 par value per share5.05,550,000.0005/12/2026 Filed 2026-05-19SCHEDULE 13GOpen filing 0002050709-26-000018 Dispute this row
Squadron Capital Management LLC Common Stock, $0.0001 par value per share5.05,550,000.0005/12/2026 Filed 2026-05-19SCHEDULE 13GOpen filing 0002050709-26-000018 Dispute this row
Matthew Sesterhenn Common Stock, $0.0001 par value per share5.05,550,000.0005/12/2026 Filed 2026-05-19SCHEDULE 13GOpen filing 0002050709-26-000018 Dispute this row
William Blank Common Stock, $0.0001 par value per share5.05,550,000.0005/12/2026 Filed 2026-05-19SCHEDULE 13GOpen filing 0002050709-26-000018 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share0.2169,096.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003479 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share0.2169,096.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003479 Dispute this row
Steven A. Cohen Common Stock, par value $0.0001 per share0.2169,096.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003479 Dispute this row
Sirenia Capital Management LP Common Stock, par value $0.0001 per share9.923,505,000.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000919574-26-003216 Dispute this row
Alex Silverstein Common Stock, par value $0.0001 per share9.923,505,000.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000919574-26-003216 Dispute this row
Wasatch Advisors LP COM STK4.74,581,761.0003/31/2026 Filed 2026-04-22SCHEDULE 13G/AAmendment 6Open filing 0000814133-26-000050 Dispute this row
OrbiMed Advisors LLC Common Stock, par value $0.0001 per share0.5521,368.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0000947871-26-000188 Dispute this row
OrbiMed Capital LLC Common Stock, par value $0.0001 per share1.0883,534.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0000947871-26-000188 Dispute this row
Lynx1 Capital Management LP Common Stock, $0.0001 par value per share7.37,098,133.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0000902664-26-001046 Dispute this row
Weston Nichols Common Stock, $0.0001 par value per share7.37,098,133.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0000902664-26-001046 Dispute this row
Soleus Private Equity Fund III, L.P. Common Stock, par value $0.0001 per share5.96,072,822.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-015656 Dispute this row
Soleus Private Equity GP III, LLC Common Stock, par value $0.0001 per share5.96,072,822.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-015656 Dispute this row
Soleus PE GP III, LLC Common Stock, par value $0.0001 per share5.96,072,822.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-015656 Dispute this row
Soleus Capital Master Fund, L.P. Common Stock, par value $0.0001 per share9.9910,361,860.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-015656 Dispute this row
Soleus Capital, LLC Common Stock, par value $0.0001 per share9.9910,361,860.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-015656 Dispute this row
Soleus Capital Group, LLC Common Stock, par value $0.0001 per share9.9910,361,860.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-015656 Dispute this row
Soleus Capital Management, L.P. Common Stock, par value $0.0001 per share9.9910,334,114.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-015656 Dispute this row
Soleus GP, LLC Common Stock, par value $0.0001 per share9.9910,334,114.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-015656 Dispute this row
Guy Levy Common Stock, par value $0.0001 per share9.9910,334,114.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-015656 Dispute this row
Morgan Stanley Common Stock9.38,974,19112/31/2025 Filed 2026-02-11SCHEDULE 13G/AAmendment 2Open filing 0000895421-26-000033 Dispute this row
Morgan Stanley Co. LLC Common Stock9.28,897,94212/31/2025 Filed 2026-02-11SCHEDULE 13G/AAmendment 2Open filing 0000895421-26-000033 Dispute this row
RA Capital Management, L.P. Common Stock, $0.0001 par value per share9.99,441,256.0010/17/2025 Filed 2025-10-24SCHEDULE 13GOpen filing 0001346824-25-000025 Dispute this row
Peter Kolchinsky Common Stock, $0.0001 par value per share9.99,441,256.0010/17/2025 Filed 2025-10-24SCHEDULE 13GOpen filing 0001346824-25-000025 Dispute this row
Rajeev Shah Common Stock, $0.0001 par value per share9.99,441,256.0010/17/2025 Filed 2025-10-24SCHEDULE 13GOpen filing 0001346824-25-000025 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,212,651 filings read, dated 2004-06-14 to 2026-11-16: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
2022130,393
2023199,811
2024209,823
2025235,520
2026260,165

Filings made before the SEC required XML are listed, not extracted.

Back to C4 THERAPEUTICS, INC.